If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Director/PDMR Shareholding

24 Jul 2012 08:05

RNS Number : 3081I
Fastnet Oil & Gas PLC
24 July 2012
 



24 July 2012

Fastnet Oil & Gas plc

Director/PDMR Shareholding

Further to the announcement of 18 July 2012, Fastnet Oil and Gas plc ("Fastnet" or the "Company") (AIM: FAST, ESM: FOI), the newly listed E&P company focussed on near term exploration acreage in the Celtic Sea and Africa, announces the interests of the Directors in the Company's issued share capital following admission of the 40,688,212 new ordinary shares in the Company issued as consideration for the acquisition of Pathfinder Hydrocarbon Ventures Limited (the "Acquisition").

Following the Acquisition

Director

Role

Number of Ordinary Shares

Percentage of Issued Share Capital

Cathal Friel1

Non-Executive Chairman

18,888,051

9.19%

Stephen Staley

CEO

3,333,183

1.62%

Michael Nolan

Non-Executive Director

3,341,243

1.63%

Michael Edelson

Non-Executive Director

922,384

0.45%

 

Note:

1. Cathal Friel's interest in Ordinary Shares in the Company includes 15,554,857 Ordinary Shares held by Raglan Road Capital Limited, a company in which Cathal Friel and his wife, Pamela Iyer, have a 90 per cent. interest

 

For further information, please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Non-Executive Chairman

Steve Staley, CEO

+353 (1) 644 0007

Shore Capital

(Nominated Adviser & Joint Broker)

Nomad

Bidhi Bhoma

Edward Mansfield

 

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

Davy

(ESM Adviser & Joint Broker)

John Frain

Brian Garrahy

Roland French

 

+353 (1) 679 6363

FTI Consulting

Billy Clegg

Edward Westropp

+44 (0) 207 831 3113

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSSEFFMDFESEDW
Date   Source Headline
7th Jan 20197:00 amRNSPositive results for gene therapy AP103
4th Jan 201912:56 pmRNSEASE Phase III trial interim efficacy results
21st Dec 20182:05 pmRNSSecond Price Monitoring Extn
21st Dec 20182:00 pmRNSPrice Monitoring Extension
19th Dec 20187:00 amRNSUpdate on ongoing AP101 Trial
10th Dec 201811:30 amRNSGrant Funding from Irish Government for AP103
17th Oct 20187:00 amRNSLojuxta to be reimbursed in France
26th Sep 20187:00 amRNSInterim Results
14th Sep 20187:00 amRNSNotice of Results
10th Sep 20187:00 amRNSAmryt receives IND approval from FDA for AP101
2nd Aug 20187:00 amRNSFDA grants Pediatric Rare Disease designation
19th Jul 20187:00 amRNSTrading update & significant momentum building
9th Jul 20187:00 amRNSNHS England approves funding for Lojuxta
6th Jul 20187:00 amRNSChange of Registered Address
25th Jun 20188:10 amRNSCompany name alteration for previous release
25th Jun 20187:00 amRNSPositive data of Pollinex Quattro Grass vaccine
5th Jun 201810:41 amRNSResult of AGM
29th May 20187:00 amRNSFour Middle East Lojuxta® Distribution Agreements
10th May 20187:00 amRNSExclusive Lojuxta® Licence Expanded
9th May 20182:48 pmRNSHolding(s) in Company
8th May 20187:00 amRNSHolding(s) in Company and Lock-in agreement
4th May 20187:00 amRNSPosting of Annual Report 2017 and Notice of AGM
17th Apr 20187:00 amRNSFinal Results
15th Mar 20187:00 amRNSTrading update & Gene therapy agreement
6th Mar 20187:00 amRNSSenior Management Appointment
6th Mar 20187:00 amRNSDistribution Agreement for Lojuxta in Middle East
2nd Mar 20187:00 amRNSNotice of Trading Update
30th Jan 20187:00 amRNSNew Distribution Agreement Signed
24th Jan 20187:00 amRNSSenior Management Team Appointment
10th Jan 20187:00 amRNSNew Distribution Agreement Signed
8th Jan 20187:00 amRNSDistribution Agreement Signed Covering Switzerland
20th Dec 20177:00 amRNSSenior Management Team Appointment
1st Dec 20177:00 amRNSGrant of Options & PDMR Dealings
20th Nov 20174:35 pmRNSPrice Monitoring Extension
13th Nov 20177:00 amRNSDistribution Agreement Signed in Saudi Arabia
13th Oct 20173:29 pmRNSHolding(s) in Company
11th Oct 20177:00 amRNSDirector Share Purchases
11th Oct 20177:00 amRNSHolding(s) in Company
11th Oct 20177:00 amRNSEnterprise Securities Market Notice
10th Oct 20177:00 amRNSEnterprise Securities Market Notice
9th Oct 201712:13 pmRNSResult of General Meeting & Completion of Placing
21st Sep 20177:00 amRNSPlacing to raise EUR 15m
4th Sep 20177:00 amRNSInterim Results
31st Aug 20177:00 amRNSAttendance at Rodman & Renshaw Conference
30th Aug 20177:00 amRNSSenior Management Appointment
23rd Aug 20178:30 amRNSNotice of Results
25th Jul 20177:00 amRNSHighly positive long-term study results - Lojuxta
25th May 201711:49 amRNSResult of AGM
25th May 20177:00 amRNSAGM Statement
27th Apr 20177:00 amRNSStudy Results of Real-World Experience of Lojuxta

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.